EXHIBIT 99.1
May 13, 2024
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: Nymox Pharmaceutical Corporation
Ladies and Gentlemen:
We have read Nymox Pharmaceutical Corporation’s Form 6-K dated May 13, 2024, and we agree with the statements set forth in the Form 6-K, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained therein.
We hereby consent to the filing of this letter as an exhibit to the foregoing report on Form 6-K.
Very truly yours,
/s/ TPS Thayer LLC |
|
TPS Thayer LLC |
|
Sugar Land, Texas |
